CT-CIDRA-MINERALS
CiDRA Minerals Processing Inc. (“CiDRA”) and OZ Minerals Ltd (“OZ Minerals”) are pleased to announce that they have entered into a Memorandum of Understanding that provides a basis of common understanding to commission a Front End Engineering Design (FEED) study for customization and tie-in of CiDRA’s proprietary mineral separation technology for operation in a grind circuit rougher application at OZ Minerals’ Carrapateena Mine Site. At the same time, CiDRA and OZ Minerals have agreed to deploy a demonstration plant based on CiDRA’s technology at the site. CiDRA and OZ Minerals share a desire to increase the technology readiness level (TRL) for a commercial scale implementation of CiDRA’s technology as a grind circuit rougher which will process a coarse fraction of the primary grind hydrocyclone underflow at Carrapateena. The goals of the Partnership are to increase plant throughput, recovery, and net metal production at a reduced specific energy consumption in keeping with their efforts to help meet the world’s raw material needs in a responsible, equitable, and sustainable way.
“We are excited to take this next step in our relationship with OZ Minerals. Since early 2022, we have been working closely with the Carrapateena Mine Site to evaluate the potential benefits of CiDRA’s technology. This new technology enables a robust process that can recover mineral particles across a size range from ultra-fine to very coarse with high selectivity and minimal hydraulic entrainment. Applying CiDRA’s novel technology as a grind circuit rougher unlocks the concentrator’s throughput capacity while maintaining world class mineral recovery. The MOU will allow us to collectively focus our efforts to leverage this incredible innovation to enhance the net metal production of the Carrapateena Mine Site and create a tremendous value for each of our companies,” stated Paul Rothman, President of CiDRA.
Joe Seppelt, Manager-Processing at OZ Minerals’ Carrapateena Mine Site stated: “The CiDRA technology can enable us to increase our plant throughput without sacrificing the industry leading recoveries that we have been able to achieve at Carrapateena. This capital efficient approach has the potential to operate with less water and energy and with a smaller footprint. We look forward to working with CiDRA to realize the benefits of their innovation.”
About CiDRA Minerals Processing
CiDRA Minerals Processing develops advanced technologies and solutions that create new paradigms in the minerals processing industry with a focus on increasing enterprise value through optimization, increased recoveries and enhancing the sustainability of limited and valuable resources. CiDRA Minerals Processing provides measurement and control solutions to over 460 mine sites in 46 countries.
About OZ Minerals
At OZ Minerals we strive to be modern. We’re guided by our purpose, “Going beyond what’s possible to make lives better”. We believe that only when we create value for all our stakeholders will we be successful and sustainable. Our framework of systems and behaviours we call The OZWay, guides us while giving us the freedom and pathways to achieve our aspirations and purpose. We are passionate about creating an inclusive culture where people challenge, innovate, learn and grow together. By ethically and responsibly exploring for and mining copper we contribute to a low carbon future and economic wellbeing which, in turn, helps us achieve our purpose and contribute to a better future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221218005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom